Balanced news tone
News Sentiment
NOX sentiment intelligence
Noxopharm Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
88/100 classification confidence.
directly relevant articles
high-authority source matches
-1.1% over one week, +18.2% over four weeks, trend inactive, and near fair-value range.
Noxopharm (ASX:NOX) Shares Ease as Investors Await Fresh Evidence From Its Biotechnology Pipeline
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Noxopharm (ASX:NOX) Shares Ease as Investors Await Fresh Evidence From Its Biotechnology Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 08:16
- Source
- Kalkine
Why Has Noxopharm (ASX: NOX) Attracted Renewed Market Attention?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Kalkine
Noxopharm CEO discusses Sofra cancer platform | ASX:NOX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Proactive financial news
Noxopharm (ASX:NOX) shares Skyrocket 40% Today- Here’s Why?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Kalkine
Noxopharm (ASX:NOX) Moves Ahead with Key Biotechnology Initiative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Kalkine
ASX All Ords Biotech: Is Noxopharm (ASX:NOX) in Focus?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Kalkine Media
Noxopharm (ASX:NOX) Shares Hold Steady Despite Promising Sofra Lung Inflammation Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Apr 2026 07:00
- Source
- Kalkine
Noxopharm (ASX:NOX) Advances SOF-SKN Program with New Preclinical Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Kalkine
Noxopharm locks in up to $5m standby equity funding via Acuity ATM
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Feb 2026 08:00
- Source
- Proactive financial news
Insights: Noxopharm Ltd (ASX:NOX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Oct 2025 15:18
- Source
- smallcaps.com.au
We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 29 Jul 2025 07:00
- Source
- simplywall.st
Just the Facts: Noxopharm
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Aug 2024 07:00
- Source
- Proactive financial news
mRNA is the next big thing in medicine. Here's why Noxopharm could be the ASX front runner in this field
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Nov 2023 07:00
- Source
- Stockhead
Noxopharm Ltd Share Price - NOX, RNS News, Articles, Quotes, & Charts (ASX:NOX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Apr 2021 15:27
- Source
- Proactive financial news
Noxopharm Limited (ASX:NOX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Sep 2019 03:15
- Source
- intelligentinvestor.com.au
NOX Stock Price and Chart — ASX:NOX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Sep 2017 09:43
- Source
- TradingView